Large language models (LLMs) for inferring genomic characteristics and facilitating genomic literacy in prostate cancer (PCa) patients.

S Syed Arsalan Ahmed Naqvi (Mayo Clinic, Phoenix, AZ) U Umair Ayub (1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States) M Muhammad Ali Khan P Peter R. Khoury (Mayo Clinic Arizona, Phoenix, AZ) D Deepak B Ravichandar (Mayo Clinic in Rochester, Rochester, MN) O Owen H. Witte (Mayo Clinic in Rochester, Rochester, MN) D Daniel S Childs (Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN) J Jacob Orme (Department of Medical Oncology, Mayo Clinic Rochester, Rochester, MN) Y Yousef Zakharia (Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA) P Parminder Singh (Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ) A Alan Haruo Bryce (Mayo Clinic Arizona, Phoenix, AZ) I Irbaz Bin Riaz (Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA)

Abstract

261 Background: Clinicians use next-generation sequencing (NGS) to tailor targeted treatments for PCa patients. However, the results are often available in unstructured formats and are saturated with technical jargon, making them inaccessible for patients. Therefore, we aimed to assess the efficacy of LLMs to accurately extract genomic characteristics from unstructured reports and generate patient-friendly summaries for ease of variant interpretation in PCa patients. Methods: This retrospective study included patients with PCa who underwent NGS from 2023-2024. The GPT4 model was utilized using structured zero-shot prompts to extract genomic characteristics from unstructured reports in a non-decomposed manner. Prompt development was conducted iteratively using a 2% random sample of the dataset. Genomic characteristics ascertained by LLM were assessed against held out vendor-curated test dataset for evaluation. Performance was assessed using weighted evaluation metrics (precision, recall, and F1-score). Additionally, the extracted variables were organized using rule-based criterion and presented as a separate prompt to GPT4 to generate summaries for interpretation at the level of each biologically relevant variant. Mean Flesch-Kincaid scores and Vocd-D statistic with standard deviations were computed to assess readability and lexical diversity of LLM-generated variant interpretation summaries. Results: A total of 331 patients (370 NGS reports) were included in the study. Evaluation on the held-out test dataset (Table) showed that the weighted average precision ranged from 80% for extracting tumor mutational burden to 100% for extracting the CtDNA fraction from unstructured reports. The weighted average recall ranged from 85% for extracting CtDNA tumor fraction to 99% for ascertaining variant/alteration. The weighted average F1-scores varied from 0.83 for extracting tumor mutational burden to 1.0 for extracting specimen site from NGS reports. The mean Flesch-Kincaid score was 8.29 ± 1 indicating average/standard readability ease. The mean Vocd-D statistic was 7.55 ± 1 indicating focused summaries, however, with limited lexical diversity. Conclusions: This study suggests that large language models can effectively extract genomic characteristics from unstructured reports and can potentially improve genomic literacy among prostate cancer patients by providing easy-to-interpret variant summaries. However, targeted prompting may be required to increase lexical diversity for improved engagement. Performance across different genomic characteristics. Category Precision Recall F1-Score Altered gene 0.86 0.97 0.89 Variant/alteration type 0.98 0.99 0.98 Variant allele fraction 0.96 0.96 0.96 Test name/type 1 0.99 1 Specimen site 1 0.99 1 Tumor mutational burden 0.8 0.93 0.83 CtDNA tumor fraction 1 0.85 0.92 MSI status 0.99 0.97 0.98

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 261-261
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (12)

S

Syed Arsalan Ahmed Naqvi

Mayo Clinic, Phoenix, AZ

U

Umair Ayub

1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States

M

Muhammad Ali Khan

P

Peter R. Khoury

Mayo Clinic Arizona, Phoenix, AZ

D

Deepak B Ravichandar

Mayo Clinic in Rochester, Rochester, MN

O

Owen H. Witte

Mayo Clinic in Rochester, Rochester, MN

D

Daniel S Childs

Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN

J

Jacob Orme

Department of Medical Oncology, Mayo Clinic Rochester, Rochester, MN

Y

Yousef Zakharia

Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA

P

Parminder Singh

Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ

A

Alan Haruo Bryce

Mayo Clinic Arizona, Phoenix, AZ

I

Irbaz Bin Riaz

Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA